Abstrakt

Przypisy

• 1. Caca‑Biljanovska N., V’lckova‑Laskoska M., Laskoski D.: Successfulmanagement of ustekinumab‑induced pustular psoriasis without therapydiscontinuation. Acta Dermatovenerol. Croat., 2013; 21: 202‑204 2 Canavan T.N., Elmets C.A., Cantrell W.L., Evans J.M., Elewski B.E.:Anti‑IL‑17 medications used in the treatment of plaque psoriasisand psoriatic arthritis: a comprehensive review. Am. J. Clin. Dermatol.,2016; 17: 33‑47
  Google Scholar
• 2. Study Group: Secukinumab, a human anti‑interleukin‑17Amonoclonal antibody, in patients with psoriatic arthritis (FUTURE2):a randomised, double‑blind, placebo‑controlled, phase 3 trial. Lancet,2015; 386: 1137‑1146
  Google Scholar
• 3. Chehab G., Sander O., Fischer‑Betz R., Schneider M.: Anti‑CD20therapy for inducing and maintaining remission in refractory systemiclupus erythematosus. Z. Rheumatol., 2007; 66: 328‑336
  Google Scholar
• 4. Day M., Nam D., Goodman S., Su E.P., Figgie M.: Psoriatic arthritis.J. Am. Acad. Orthop. Surg., 2012; 20: 28‑37
  Google Scholar
• 5. Gordon K.B., Duffin K., Bissonnette R., Prinz J.C., Wasfi Y., Li S.,Shen Y.K., Szapary P., Randazzo B., Reich K.: A phase 2 trial of guselkumabversus adalimumab for plaque psoriasis. N. Engl. J. Med.,2015; 373: 136‑144
  Google Scholar
• 6. Gottlieb A., Menter A., Mendelsohn A., Shen Y.K., Li S., GuzzoC., Fretzin S., Kunynetz R., Kavanaugh A.: Ustekinumab, a humaninterleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized,double‑blind, placebo‑controlled, crossover trial. Lancet,2009; 373: 633‑640
  Google Scholar
• 7. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., GoffeB.S., Gaspari A.A., Ling M., Weinstein G.D., Nayak A., Gordon K.B.,Zitnik R.: A randomized trial of etanercept as monotherapy for psoriasis.Arch. Dermatol., 2003; 139: 1627‑1632
  Google Scholar
• 8. Guidelli G.M., Fioravanti A., Rubegni P., Feci L.: Induced psoriasisafter rituximab therapy for rheumatoid arthritis: a case reportand review of the literature. Rheumatol. Int., 2013; 33: 2927‑2930
  Google Scholar
• 9. Guillot B.: Quoi de neuf en thérapeutique dermatologique? Ann.Dermatol. Venereol., 2013; 140 (Suppl. 3): S293‑S302
  Google Scholar
• 10. Jahnz‑Różyk K.: Dostępność leków biologicznych w Polsce i naświecie. Przew. Lek., 2010; 6: 14‑16
  Google Scholar
• 11. Jenerowicz D.: Terapia biologiczna w wybranych chorobachskóry. Przew Lek., 2006; 7: 92‑99
  Google Scholar
• 12. Jimenez‑Boj E., Stamm T.A., Sadlonova M., Rovensky J., RaffayováH., Leeb B., Machold K.P., Graninger W.B., Smolen J.S.: Rituximabin psoriatic arthritis: an exploratory evaluation. Ann. Rheum. Dis.,2012; 71: 1868‑1871References
  Google Scholar
• 13. Kavanaugh A., Ritchlin C., Rahman P., Puig L., Gottlieb A.B., Li S.,Wang Y., Noonan L., Brodmerkel C., Song M., Mendelsohn A.M., McInnesI.B.: Ustekinumab, an anti‑IL‑12/23 p40 monoclonal antibody, inhibitsradiographic progression in patients with active psoriatic arthritis: resultsof an integrated analysis of radiographic data from the phase 3,multicentre, randomised, double‑blind, placebo‑controlled PSUMMIT‑1and PSUMMIT‑2 trials. Ann. Rheum. Dis., 2014; 73: 1000‑1006
  Google Scholar
• 14. Kim I.H., West C.E., Kwatra S.G., Feldman S.R., O’Neill J.L.: Comparativeefficacy of biologics in psoriasis: a review. Am J. Clin. Dermatol.,2012; 13: 365‑374
  Google Scholar
• 15. Larsen C.G., Andersen P.H., Lorentzen H., Zachariae C.,Huldt‑Nystrøm T., Dotterud L.K., Lindkvist R.M., Qvitzau S.: Clinicaland economic impact of etanercept in real‑life: a prospective,non‑interventional study of etanercept in the treatment of patientswith moderate to severe plaque psoriasis in private dermatologistsettings (ESTHER). Eur. J. Dermatol., 2013; 23: 774‑781
  Google Scholar
• 16. Lebre M.C., Jonckheere C.L., Kraan M.C., van Kuijk A.W., Bos J.D.,de Rie M., Gerlag D.M., Tak P.P.: Expression of IL‑20 in synovium andlesional skin of patients with psoriatic arthritis: differential responseto alefacept treatment. Arthritis Res. Ther., 2012; 14: R200
  Google Scholar
• 17. Lebwohl M.G., Kircik L., Callis Duffin K., Pariser D., Hooper M.,Wenkert D., Thompson E.H., Yang J., Kricorian G., Koo J.: A randomizedstudy to evaluate the efficacy and safety of adding topicaltherapy to etanercept in patients with moderate to severe plaquepsoriasis. J. Am. Acad. Dermatol., 2013; 69: 385‑392
  Google Scholar
• 18. Lembo S., Capasso R., Balato A., Cirillo T., Flora F., Zappia V., BalatoN., Ingrosso D., Ayala F.: MCP‑1 in psoriatic patients: effect ofbiological therapy. J. Dermatolog. Treat., 2014; 25: 83‑86
  Google Scholar
• 19. Leonardi C.L., Kimball A.B., Papp K.A, Yeilding N., Guzzo C., WangY., Li S., Dooley L.T., Gordon K.B.; PHOENIX 1 study investigators: Efficacyand safety of ustekinumab, a human interleukin‑12/23 monoclonalantibody, in patients with psoriasis: 76‑week results froma randomized, double‑blind, placebo‑controlled trial (PHOENIX 1).Lancet, 2008; 371: 1665‑1674
  Google Scholar
• 20. Lora V., Bonaguri C., Gisondi P., Sandei F., Battistelli L., RussoA., Melegari A., Trenti T., Lippi G., Girolomoni G.: Autoantibody inductionand adipokine levels in patients with psoriasis treated withinfliximab. Immunol. Res., 2013; 56: 382‑389
  Google Scholar
• 21. López‑Ferrer A., Vilarrasa E., Gich I.J., Puig L.: Adalimumabfor the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br. J. Dermatol., 2013; 169:1141‑1147
  Google Scholar
• 22. Mälkönen T.: New biological drugs in the treatment of inflammatoryskin diseases. Duodecim, 2014; 130: 627‑634
  Google Scholar
• 23. McInnes I.B., Mease P.J., Kirkham B., Kavanaugh A., Ritchlin C.T.,Rahman P., van der Heijde D., Landewé R., Conaghan P.G., GottliebA.B., Richards H., Pricop L., Ligozio G., Patekar M., Mpofu S., FUTURE
  Google Scholar
• 24. M de la Brassinne, Nikkels A.F.: Psoriasis: state of the art 2013.Part II. Therapeutics. Acta Clin. Belg., 2013; 68: 433‑441
  Google Scholar
• 25. Menter A.: The status of biologic therapies in the treatment ofmoderate to severe psoriasis. Cutis, 2009; 84 (Suppl. 4): 14‑24
  Google Scholar
• 26. Menting S.P., Coussens E., Pouw M.F., van den Reek J.M., TemmermanL., Boonen H., de Jong E.M., Spuls P.I., Lambert J.: Developinga therapeutic range of adalimumab serum concentrations inmanagement of psoriasis: a step toward personalized treatment.JAMA Dermatol., 2015; 151: 616‑622
  Google Scholar
• 27. Nakae S., Nambu A., Sudo K., Iwakura Y.: Suppresion of immuneinduction of collagen‑induced arthritis in IL‑17‑deficient mice. J.Immunol., 2003; 171: 6173‑6177
  Google Scholar
• 28. Papoutsaki M., Osório F., Morais P., Torres T., Magina S., ChimentiS., Costanzo A.: Infliximab in psoriasis and psoriatic arthritis. BioDrugs,2013; 27 (Suppl. 1): 13‑23
  Google Scholar
• 29. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P.,Yeilding N., Guzzo C., Hsu M.C., Wang Y., Li S., Dooley L.T., Reich K.;PHOENIX 2 study investigators: Efficacy and safety of ustekinumab,a human interleukin‑12/23 monoclonal antibody, in patientswith psoriasis: 52‑week results from a randomized, double‑blind,placebo‑controlled trial (PHOENIX 2). Lancet, 2008; 371: 1675‑1684
  Google Scholar
• 30. Piaserico S., Conti A., Lo Console F., De Simone C., Prestinari F.,Mazzotta A., Gualdi G., Guarneri C., Borsari S., Cassano N.: Efficacyand safety of systemic treatments for psoriasis in elderly patients.Acta Derm. Venereol., 2014; 94: 293‑297
  Google Scholar
• 31. Puig L.: Treatment of moderate to severe plaque psoriasis withbiologics: analysis of the additional cost of temporary dose escalationvs switch to another biologic after failure of maintenancetherapy. Actas Dermosifiliogr., 2014; 105: 401‑412
  Google Scholar
• 32. Reich A., Szepietowski J.: Etanercept istotnie poprawia jakośćżycia pacjentów z łuszczycą: przegląd aktualnego piśmiennictwa.Dermatol. Klin., 2007; 9: 189‑191
  Google Scholar
• 33. Rich P., Bourcier M., Sofen H., Fakharzadeh S., Wasfi Y., WangY., Kerkmann U., Ghislain P.D., Poulin Y.; PHOENIX 1 investigators:Ustekinumab improves nail disease in patients with moderate‑to‑severepsoriasis: results from PHOENIX 1. Br. J. Dermatol., 2014; 170:398‑407
  Google Scholar
• 34. Salomon J., Szepietowski J.: Ustekinumab – nowy lek biologicznyw leczeniu łuszczycy. Przegl. Dermatol., 2010; 97: 61‑67
  Google Scholar
• 35. Scheinfeld N.: Alefacept: a safety profile. Expert Opin. DrugSaf., 2005; 4: 975‑985
  Google Scholar
• 36. Smith R.L., Warren R.B., Eyre S., Ho P., Ke X., Young H.S., GriffithsC.E., Worthington J.: Polymorphisms in the IL‑12β and IL‑23R genesare associated with psoriasis of early onset in a UK cohort. J. Invest.Dermatol., 2008; 128: 1325‑1327
  Google Scholar
• 37. Stamell E.F., Kutner A., Viola K., Cohen S.R.: Ustekinumab associatedwith flares of psoriaticarthritis. JAMA Dermatol., 2013; 149:1410‑1413
  Google Scholar
• 38. Stelara (ustekinumab): Summary of product characteristics.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‑_Product_Information/human/000958/WC500058513.pdf(12.10.2016)
  Google Scholar
• 39. Szepietowski J., Adamski Z., Chodorowska G., Gliński W., KaszubaA., Placek W., Rudnicka L., Reich A.: Rekomendacje Polskiego TowarzystwaDermatologicznego dotyczące stosowania leków biologicznychw łuszczycy zwyczajnej i stawowej (łuszczycowym zapaleniustawów). Przegl. Dermatol., 2010; 97: 1‑13
  Google Scholar
• 40. Szodoray P., Alex P., Chappell‑Woodward C.M., Madland T.M.,Knowlton N., Dozmorov I., Zeher M., Jarvis J.N., Nakken B., BrunJ.G., Centola M.: Circulating cytokines in Norwegian patients withpsoriatic arthritis determined by a multiplex cytokine array system.Rheumatology, 2007; 46: 417‑425
  Google Scholar
• 41. Tyc‑Zdrojewska E., Kaszuba A., Michalak I., Kaszuba A.: Preparatybiologiczne w terapii łuszczycy – doświadczenia własne. Forum MedycynyRodzinnej, 2009; 3: 468‑479
  Google Scholar
• 42. van den Reek J.M., van Lümig P.P., Kievit W., Zweegers J., vande Kerkhof P.C., Seyger M.M., de Jong E.M.: Effectiveness of adalimumabdose escalation, combination therapy of adalimumab withmethotrexate, or both in patients with psoriasis in daily practice. J.Dermatolog. Treat., 2013; 24: 361‑368
  Google Scholar
• 43. Weitz J.E., Ritchlin C.T.: Ustekinumab: targeting the IL‑17 pathwayto improve outcomes in psoriatic arthritis. Expert Opin. Biol.Ther., 2014; 14: 515‑526
  Google Scholar
• 44. Withdrawal of the marketing authorisation application for Ozespa(briakinumab). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/01/WC500101402.pdf(15.08.2014)
  Google Scholar
• 45. Yiu Z.Z., Griffiths C.E.: Interleukin 17‑A inhibition in the treatmentof psoriasis. Expert Rev. Clin. Immunol., 2016; 12: 1‑4
  Google Scholar

Pełna treść artykułu